Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, older age was found to predict lateral hairline recession in TGNB AMAB individuals, while each year of feminizing hormone therapy in patients over 30 also predicted a decrease in lateral forehead length by 0.07 cm.

In this retrospective chart review, researchers observed that estrogen monotherapy effectively suppressed testosterone levels below 50ng/dL in all transfeminine patients studied, particularly those using injectable formulations, though the small sample size and ongoing data collection limit these findings.

In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.

This commentary highlights that transgender patients are often dissatisfied with standard hormone replacement therapy for hair-related goals, emphasizing the need for dermatologists to provide informed guidance and tailor treatments.

This commentary examines whether 5α-reductase inhibitors are effective and safe for transfeminine and transmasculine individuals, highlighting the lack of efficacy and safety data in gender diverse populations and suggesting that clinicians discuss potential benefits and risks with patients considering their use.